FDA Expands Indication for Sotatercept-csrk in Pulmonary Arterial Hypertension
FDA Expands Indication for Sotatercept-csrk in Pulmonary Arterial Hypertension The FDA has approved an updated indication for sotatercept-csrk (WINREVAIR), an activin signaling inhibitor, …